These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26002752)

  • 1. Prognostic factors for overall survival in metastatic colorectal cancer using a stop-and-go FLIRI-based treatment strategy.
    Kronborg CS; Jensen AR
    Int J Colorectal Dis; 2015 Aug; 30(8):1059-65. PubMed ID: 26002752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of treatment-related factors in metastatic colorectal cancer using a stop-and-go strategy.
    Kronborg CJ; Jensen AR
    Int J Colorectal Dis; 2014 Dec; 29(12):1453-8. PubMed ID: 25064391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical Resection of Primary Tumor in Asymptomatic or Minimally Symptomatic Patients With Stage IV Colorectal Cancer: A Canadian Province Experience.
    Ahmed S; Fields A; Pahwa P; Chandra-Kanthan S; Zaidi A; Le D; Haider K; Reeder B; Leis A
    Clin Colorectal Cancer; 2015 Dec; 14(4):e41-7. PubMed ID: 26140732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer.
    Ahmed S; Pahwa P; Le D; Chalchal H; Chandra-Kanthan S; Iqbal N; Fields A
    Clin Colorectal Cancer; 2018 Jun; 17(2):e201-e206. PubMed ID: 29221688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
    van Rooijen KL; Shi Q; Goey KKH; Meyers J; Heinemann V; Diaz-Rubio E; Aranda E; Falcone A; Green E; de Gramont A; Sargent DJ; Punt CJA; Koopman M
    Eur J Cancer; 2018 Mar; 91():99-106. PubMed ID: 29353165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study.
    Ahmed S; Leis A; Fields A; Chandra-Kanthan S; Haider K; Alvi R; Reeder B; Pahwa P
    Cancer; 2014 Mar; 120(5):683-91. PubMed ID: 24222180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
    Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
    Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
    Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent.
    Wong SF; Wong HL; Field KM; Kosmider S; Tie J; Wong R; Tacey M; Shapiro J; Nott L; Richardson G; Cooray P; Jones I; Croxford M; Gibbs P
    Clin Colorectal Cancer; 2016 Sep; 15(3):e125-32. PubMed ID: 26803709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic factors of patients with unresectable liver metastasis from colorectal cancer after failed conversion chemotherapy].
    He H; Shen W; Chen W; Liu H; Gong W; Fu J; Hu X; Cui L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1261-1267. PubMed ID: 30506537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
    Yuste AL; Aparicio J; Segura A; López-Tendero P; Gironés R; Pérez-Fidalgo JA; Díaz R; Calderero V
    Clin Colorectal Cancer; 2003 Feb; 2(4):231-4. PubMed ID: 12620142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases.
    Yu Q; Zhang L; Fan S; Huang L; Wang X; Xindun C
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C205-C211. PubMed ID: 28230018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is complete liver resection without resection of synchronous lung metastases justified?
    Mise Y; Kopetz S; Mehran RJ; Aloia TA; Conrad C; Brudvik KW; Taggart MW; Vauthey JN
    Ann Surg Oncol; 2015 May; 22(5):1585-92. PubMed ID: 25373535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases.
    Yamashita S; Odisio BC; Huang SY; Kopetz SE; Ahrar K; Chun YS; Conrad C; Aloia TA; Gupta S; Harmoush S; Hicks ME; Vauthey JN
    Eur J Surg Oncol; 2017 Jun; 43(6):1040-1049. PubMed ID: 28187878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases.
    Facciorusso A; Del Prete V; Crucinio N; Serviddio G; Vendemiale G; Muscatiello N
    World J Gastroenterol; 2016 Apr; 22(16):4211-8. PubMed ID: 27122671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of D-dimer correlated with disease status and poor prognosis of inoperable metastatic colorectal cancer patients treated with bevacizumab.
    Zhu L; Liu B; Zhao Y; Liu L; Yang C; Yang Y; Zhong H
    J Cancer Res Ther; 2014 Dec; 10 Suppl():246-51. PubMed ID: 25693928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
    Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
    Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.